Clinical Trials Browser

Phase 1 × Interventional × binimetinib × Clear all

Neoplasm Metastasis, Triple Negative Breast Neoplasms

Lung Neoplasms

Carcinoma, Non-Small-Cell Lung, Glioma, Melanoma, Thyroid Neoplasms

Non-small Cell Carcinoma

Brain Diseases, Brain Neoplasms, Carcinoma, Non-Small-Cell Lung, Melanoma, Neoplasms, Central Nervous System Neoplasms

Carcinoma, Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

Parkinson Disease 4, Autosomal Dominant Lewy Body, Spinocerebellar Degenerations, Colorectal Neoplasms

Carcinoma, Non-Small-Cell Lung, Neurofibromatosis 1, Hereditary Sensory and Autonomic Neuropathies, Colorectal Neoplasms

Carcinoma, Non-Small-Cell Lung

Advanced KRAS Positive Metastatic Colorectal Cancer

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Disease Progression

Lung Neoplasms

Colorectal Neoplasms

Gastrointestinal Stromal Tumors

Pancreatic Neoplasms, Triple Negative Breast Neoplasms

Ovarian Neoplasms, Pancreatic Neoplasms, Triple Negative Breast Neoplasms

Advanced Solid Tumor

Advanced Solid Tumors

Biliary Tract Neoplasms, Colonic Neoplasms, Rectal Neoplasms, Colorectal Neoplasms

Carcinoma, Ovarian Epithelial, Fallopian Tube Neoplasms

Carcinoma, Non-Small-Cell Lung

Blast Crisis, Leukemia, Leukemia, Myeloid, Chronic-Phase

Colonic Neoplasms, Rectal Neoplasms

Advanced and Selected Solid Tumors

Clinical Trials

Testing the Combination of the Anticancer Drugs ZEN003694 and Binimetinib in Patients With Advanced/Metastatic or Unresectable Solid Tumors With RAS Alterations and Triple Negative Breast Cancer

Study of Palbociclib in Combination With Binimetinib for Patients With Advanced KRAS Mutant Non-Small Cell Lung Cancer

A Study to Learn About the Study Medicine Called PF-07799933 in People With Advanced Solid Tumors With BRAF Alterations.

BiniPembro

A FIH Study of PF-07284890 in Participants With BRAF V600 Mutant Solid Tumors With and Without Brain Involvement

MEK162

KEYNOTE-651

PF-07284892 in Participants With Advanced Solid Tumors

Phase 1b/2 Study of Futibatinib in Combination With Binimetinib in Patients With Advanced KRAS Mutant Cancer

Bioequivalence Binimetinib 3 x 15 mg and 45 mg Formulations

A Trial of mFOLFIRI With MEK162 in Patients With Advanced RAS (HRAS, NRAS, or KRAS) Positive Metastatic Colorectal Cancers

Study of the Combination of Binimetinib and Encorafenib in Adolescent Patients With Unresectable or Metastatic BRAF V600-mutant Melanoma

Hepatic Impairment Study of Encorafenib in Combination With Binimetinib in BRAF Melanoma

A Phase I/IB Trial of MEK162 in Combination With Erlotinib in NSCLC Harboring KRAS or EGFR Mutation

Brigatinib and Binimetinib in Treating Patients With Stage IIIB-IV ALK or ROS1-Rearranged Non-small Cell Lung Cancer

Relative Bioavailability of Binimetinib 3 x 15 mg and 45 mg Formulations

Binimetinib in Addition to Standard Chemotherapy in KRAS Mutated NSCLC.

MErCuRIC1

A Study of MEK162 (Binimetinib) in Combination With Pexidartinib in Patients With Advanced Gastrointestinal Stromal Tumor (GIST)

Safety, Pharmacokinetics and Pharmacodynamics of BEZ235 Plus MEK162 in Selected Advanced Solid Tumor Patients

Safety, Pharmacokinetics and Pharmacodynamics of BKM120 Plus MEK162 in Selected Advanced Solid Tumor Patients

A Phase I Study of Oral MEK162 in Japanese Patients With Advanced Solid Tumors

MEK162 and RAF265 in Adult Patients With Advanced Solid Tumors Harboring RAS or BRAFV600E Mutations

A Study of ARRY-438162 (MEK162) in Patients With Advanced Cancer

A Study of MEK162 and Paclitaxel in Patients With Epithelial Ovarian, Fallopian Tube or Peritoneal Cancer

Binimetinib With Docetaxel in Treating Patients With Previously Treated, Stage IV Non-small Cell Lung Cancer

An Open-Label, Phase I/II Study of Nilotinib (Tasigna) and MEK-162 (ARRY-162) Used in Combination for Patients With Refractory or Advanced Chronic Myeloid Leukemia and Philadelphia Positive Acute Leukemia (Protocol CAMN107AUS41T)

MEK Inhibitor MEK162 in Combination With Leucovorin Calcium, Fluorouracil, and Oxaliplatin in Treating Patients With Advanced Metastatic Colorectal Cancer

A Phase Ib Study of MEK162 Plus BYL719 in Adult Patients With Selected Advanced Solid Tumors